Aurealis Therapeutics

Aurealis Therapeutics

Biotechnology Research Kuopio, Pohjois-savo, Fi 18 employees
Employees
18
Contacts
3
Emails
3
Phones
1

Aurealis Therapeutics Overview

Headquarters
Kuopio, Pohjois-savo, Fi
Phone Number
Available in AeroLeads
Industry
Biotechnology Research
Employees
18
Founded
2015
Funding
9.0M
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Aurealis Therapeutics

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.

Aurealis Therapeutics Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage
Phone contacts
1
25.0% coverage

Aurealis Therapeutics Org Chart

Sample employees and titles
Name Title Contact
Ralf Rosenow
View
Laurent Decory Chief Operating Officer @Aurealis Therapeutics - C-suite and Board Executive - Biotech - Cell & Gene Therapy
Email Phone
Igor Mierau Director Genetic Engineering and Manufacturing at Aurealis Therapeutics
Email
Haritha Samaranayake Chief Medical Officer at Aurealis Therapeutics
Email

Employees by Management Level

Executive 2 profiles
Director 2 profiles
Manager 1 profile

Compare Similar Companies to Aurealis Therapeutics